In a research update to clients today, Brown maintained his one-year price target of $5.80 on Canopy Growth Corp., but lowered his rating on the stock from “Buy” to “Hold”.
Brown explains that he thinks Canopy will ultimately be one of the winners in the space and says current investors should hold onto their stock.
“We believe investors should continue to hold CGC given our long-term outlook of the company being a dominant player in the dual medical + recreational cannabis market, opportunities for strategic international transactions (export agreements, equity ownerships, JVs), and significant expansion capacity at its multiple facilities,” says the analyst. “Nothing has changed fundamentally over the past 1.5 months that would have us revise our estimates; however, we believe CGC’s valuation looks frothy when taking into account a reasonable investment horizon. Our valuation methodology applies an EV/adj. EBITDA multiple to a CY2020E adj. EBITDA estimate and discounts the market value per share back at 15.0%/year. We use a CY2020E adj. EBITDA estimate as we believe 2.5 years of a rec-legal market better captures the opportunity ahead of the Canadian MMJ companies while remaining within a sensible investment horizon.”
Brown believes Canopy will generate EBITDA of $600,000 on revenue of $39.4-million in fiscal 2017. He expects those numbers will improve to EBITDA of $10.5-million on a topline of $67.3-million the following year.
TD Cowen analyst Vince Valentini upgraded Telus (Telus Stock Quote, Chart, News, Analysts, Financials TSX:T) to “Buy” from “Hold”, saying… [Read More]
Roth Capital Markets analyst Scott Stember maintained a “Neutral” rating on Polaris (Polaris Stock Quote, Chart, News, Analysts, Financials NYSE:PII)… [Read More]
National Bank Financial analyst Richard Tse said the impact of AI on tech valuations is becoming more company-specific, with names… [Read More]
ScotiaMcLeod Newman Group advisor and portfolio manager Greg Newman told BNN Bloomberg’s Market Call on April 24 that Meta Platforms … [Read More]
Goodreid Investment Counsel president and CEO Gordon Reid told BNN Bloomberg’s Market Call on April 23 that McKesson (McKesson Stock… [Read More]
Beacon Securities analyst Russell Stanley initiated coverage of Metatek-Group (Metatek-Group Stock Quote, Chart, News, Analysts, Financials TSX:MTEK) with a “Buy”… [Read More]
View Comments
I'm up 150% on my stock, made about $1200 so far. Shows no sign of stopping.
except for today lol..,
It seems to do that every Friday. All weed stocks seem to. Which is fine, other days gains off set that.
I'm up 90% on my stock per today's drop, made a good $3500 so far, keep going green rush! Make me rich!
California is polling 60% in favor of approving regulated re-legalization.This stock is highly likely to go parabolic in November. Americans just do not trade like the Canuckistanis. We don't have very much in the way of impulse control, a deeply seated suspicion of securities with very low prices and not very many publicly traded companies in the space to choose from.
No chance. They own 50% of the Canadian market and are about to release three Snoop Dogg strains.
Took profits on this. Don't get greedy folks. Greed kills.
bought at 2.90, up %150. think it will go back down to 2.90 so i can buy more?
There's no way is dropping that far. If you didn't get a bunch of shares back then you're stuck.
GOOD MEDICAL marijuana/weeds,Cannabis Oil , Butane Hash Oil (BHO), CO2 Oil, Rick Simpson Oil (RSO), Tinctures cannabis, Shatter, Wax, Bubble Hash, Cannabis Butter/Oil, Iso hash oil, kief hash, HEMP their SEEDS visit my website for more infos.
website : marijuanaweedsforsale.com
,weeds,hempoil,wax,hash,shatter and MDMA (Ecstasy or Molly),pain relief,anxiety medication,Weight loss pills. oxy ,roxy ,xanax..
visit my website for more infos.
website : marijuanaweedsforsale.com
It's great to see the Cannabis industry booming. All the time, more and more people are realizing the amazing benefits of this amazing plant!!!